Qualigen Therapeutics Bolsa (NASDAQ: QLGN)

Últimas noticias sobre Qualigen Therapeutics (NASDAQ:QLGN) Bolsa

Qualigen Therapeutics

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

News

Eurozone

Markets

Trading Ideas

APLD

EAST

HOTH

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SGLY

SIFY

Mercados mixtos en EE.UU. el jueves, con el Nasdaq subiendo un 0,2% y Dow Jones ganando un 0,06%. Sectores de consumo lideran alzas.

Mercados mixtos mientras los subsidios por desempleo de EEUU caen

Qualigen Therapeutics Inc

<ul>
<li>New and updated data for MK-1084, an investigational KRAS G12C inhibitor, from the colorectal cancer and non-small cell lung cancer cohorts of the Phase 1 KANDLELIT-001 study will be presented</li>
<li>Zilovertamab vedotin and sacituzumab tirumotecan data to highlight progress in Merck's pipeline of innovative antibody-drug conjugates</li>
<li>Follow-up data for KEYTRUDA&#xAE; (pembrolizumab) and WELIREG&#xAE; (belzutifan), as well as new and updated analyses for KEYTRUDA in earlier stages of cancer, add to the body of evidence supporting the role of these medicines</li>
</ul>

Merck Highlights MK-1084 Data From KANDLELIT-001 in KRAS G12C-Mutated Colorectal And Lung Cancers At ASCO 2025

Full Year 2025 Outlook and Guidance Policy Given lower U.S. multi-state jackpot activity and the current worsening macroeconomic environment, the Company now expects revenue of approximately $2.55 billion and Adjusted EBITDA of approximately $1.10 billion, which align with the low end of the original ranges provided in February 2025; cash from operations is now expected to be a use of approximately $350 million, primarily to account for the incremental FX impact on the first two installments of the Italy Lotto license fee.
The Company provides guidance of select information related to its financial and operating performance, and such measures may differ from year to year. The guidance is only an estimate of what the Company believes is realizable as of the date of this release. Actual results will vary from the guidance and the variations may be material. The Company undertakes no intent or obligation to publicly update or revise any of these projections, whether as a result of new information, future events or otherwise, except as required by law.

Guidance

Intl Game Tech Narrows FY2025 Sales Guidance from $2.55B-$2.65B to $2.55B vs $2.57B Est

Jefferies analyst Kelly Shi initiates coverage on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announces Price Target of $105.

Price Target

Initiation

Analyst Ratings

INSM

Jefferies Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $105

Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.11 by 18.18 percent. This is a 67.86 percent decrease over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $583.00 million which missed the analyst consensus estimate of $627.84 million by 7.14 percent. This is a 11.80 percent decrease over sales of $661.00 million the same period last year.

Earnings Misses

Intl Game Tech Q1 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $583.00M Miss $627.84M Estimate

Needham analyst Ryan Koontz reiterates Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy and maintains $28 price target.

Reiteration

RKLB

Needham Reiterates Buy on Rocket Lab USA, Maintains $28 Price Target

CNCK

Coincheck Group Q1 Sales $764.00M Up From $676.00M YoY, Net Profit $4.3M Down From $13M YoY

DA Davidson analyst Rudy Kessinger downgrades Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Neutral to Underperform and lowers the price target from $29 to $21.

Downgrades

DA Davidson Downgrades Rapid7 to Underperform, Lowers Price Target to $21

Compass Point analyst Merrill Ross downgrades NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) from Buy to Neutral and lowers the price target from $50 to $42.5.

NXRT

Compass Point Downgrades NexPoint Residential to Neutral, Lowers Price Target to $42.5

JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 48.72 percent increase over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $41.49 billion which beat the analyst consensus estimate of $40.20 billion by 3.21 percent. This is a 15.20 percent increase over sales of $36.02 billion the same period last year.

Earnings Beats

CORRECTION: JD.com Q1 Adj. EPADS $1.16 Beats $1.05 Estimate, Sales $41.49B Beat $40.20B Estimate

Compass Point analyst Merrill Ross downgrades Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Buy to Neutral and announces $22 price target.

Compass Point Downgrades Independence Realty Trust to Neutral, Announces $22 Price Target

China firmly rejected responsibility for the U.S. fentanyl crisis on Tuesday, calling Washington&#8217;s punitive tariffs unreasonable even as broader trade tensions between the world&#8217;s two largest economies show signs of easing.
What Happened: &#8220;The responsibility of tackling the fentanyl issue in the United States lies within the U.S. itself,&#8221; Chinese foreign ministry spokesperson Lin Jian stated during a regular press briefing, according to Reuters. Lin was responding to questions about whether fentanyl would be discussed in future trade negotiations.
The comments come just days after both nations pledged to significantly reduce tariffs following productive talks in Switzerland. Despite this progress, the U.S. maintained its 20% tariffs specifically tied to fentanyl, claiming Beijing hasn&#8217;t done enough to stem the flow of precursor chemicals used to manufacture the deadly opioid.
See Also: <a href="https://www.benzinga.com/markets/equities/25/05/45368550/apple-may-up-its-numbers-amid-china-tariff-truce-trump-talks-500-billion-us-investment-after-tim-cook-call">Apple May &#8216;Up Its Numbers&#8217; Amid China Tariff Truce: Trump Talks $500 Billion US Investment After Tim Cook Call</a>
Why It Matters: President Donald Trump&#8216;s Monday executive order decreased general <a href="https://www.benzinga.com/government/regulations/25/05/45368852/trump-lowers-de-minimis-tariff-on-chinese-imports-from-120-to-54-pauses-200-postal-fee-amid-90-day-trade-shift">Chinese import tariffs to 10% for a 90-day negotiation period</a> and reduced the de minimis rate on low-value imports from 120% to 54%, effective Tuesday. However, the fentanyl-related tariffs remained intact.
Analysts suggest the fentanyl issue could become a <a href="https://www.benzinga.com/news/global/25/05/45188171/china-pushes-for-special-envoys-as-direct-deal-with-trump-deemed-risky-plans-fentanyl-concessions-as-negotiating-leverage-report">strategic bargaining chip in upcoming negotiations</a>. &#8220;Beijing is hoping to use fentanyl cooperation as either a catalyst for U.S.-China trade talks or a bargaining chip in a future round of negotiations,&#8221; Jeremy Chan of Eurasia Group said.
Morgan Stanley economists project that continued negotiations could potentially lower overall tariffs on Chinese imports to 34% by the end of 2025, which would indicate the eventual elimination of the 20% fentanyl-specific tariff if sufficient progress is made on addressing U.S. concerns.
Image Via Shutterstock 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/restaurants/25/05/45369152/mcdonalds-launches-massive-summer-hiring-drive-for-375000-workers-amid-us-expansion-plans-and-slumping-sales">McDonald&#8217;s Launches Massive Summer Hiring Drive For 375,000 Workers Amid US Expansion Plans And Slumping Sales</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Economics

China Rejects US Blame For Fentanyl Crisis, Calls Tariff Penalties Unreasonable Amid Easing Trade Tensions

Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) affirms FY2025 FFO guidance from $0.57-$0.61 to $0.57-$0.61 vs $0.54 analyst estimate. Affirms FY2025 sales outlook from $183.39 million-$188.17 million to $183.39 million-$188.17 million vs $186.60 million estimate.

SOHO

Sotherly Hotels Affirms FY2025 FFO Guidance of $0.57-$0.61 vs $0.54 Est; Affirms FY2025 Sales Guidance of $183.39M-$188.17M vs $186.60M Est

The shares of Avic Chengdu Aircraft, known for manufacturing fighter jets like the JF-17 Thunder and the J-10C Vigorous Dragon, saw a 41.08% surge over the past five days since the commencement of the<a href="https://www.benzinga.com/news/global/25/05/45335338/trump-makes-india-pakistan-ceasefire-declaration-in-casual-manner-thank-you-for-your-attention-to-this-matter"> India-Pakistan conflict.</a>
What Happened: This rise was amid growing tensions between India and Pakistan following New Delhi&#8217;s recent military actions to avenge the alleged killings of tourists by <a href="https://www.benzinga.com/news/global/25/05/45369837/piers-morgan-tears-into-pakistani-expert-who-says-isi-didnt-know-osama-bin-laden-was-living-near-military-base-all-they-had-to-do-was-get-a-pair-of-binoculars">Pakistani terrorists</a> in Pahalgam, Kashmir.
On Friday, U.S. officials confirmed that a Chinese-made J-10 fighter jet fired air-to-air missiles at Indian aircraft, reportedly resulting in the downing of a French-built Rafale jet. The Pakistani Defense Minister, Khawaja Muhammad Asif, also said that the Chinese-made J-10 was used to shoot down three of India's newly acquired Rafale jets. 
Notably, the Indian military has not issued a clear response to the claim. "We are in a combat scenario and losses are a part of it. All our pilots are back home," stated Air Marshal A.K. Bharti on Sunday.
However, after a steep rise, the Avic Chengdu stock tumbled over 7% on Tuesday, possibly in response to a statement from Indian Prime Minister Narendra Modi. Modi on Monday announced the successful completion of Operation Sindoor. This statement triggered a massive selloff in Chinese defense stocks.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45354990/scottie-pippen-declares-altcoin-season-as-ethereum-xrp-dogecoin-shiba-inu-rally" target="_blank" rel="noreferrer noopener">Scottie Pippen Declares &#8216;Altcoin Season&#8217; As Ethereum, XRP, Dogecoin, Shiba Inu Rally &#8211; Benzinga</a>
Why It Matters: If confirmed, this would be the first combat success of the J-10 family since the original J-10 was unveiled 27 years ago. Pakistan, a long-standing ally of China, is the only foreign country operating the advanced J-10C, with a fleet of 20. This incident also marked the first reported loss of a Rafale fighter jet in combat, according <a href="https://www.scmp.com/news/china/military/article/3309781/j-10cs-deepseek-moment-beijing-muted-china-cheers-fighter-jet-combat-reports">to</a> the South China Morning Post.
While Chinese citizens praised the J-10C fighter jet&#8217;s role in the India-Pakistan conflict as a milestone for China&#8217;s defense industry, Beijing maintained a cautious stance. Analysts attributed this to geopolitical sensitivities and military prudence. The only official response from Beijing urged both countries to show restraint and avoid escalating tensions, reported the publication. 
Meanwhile, this incident had sent <a href="https://www.benzinga.com/25/05/45342121/chinese-made-pakistani-jet-downs-two-indian-aircraft">shockwaves across defense circles </a>and rattled investors, causing shares of French manufacturer Dassault Aviation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DUAVF#OTC">DUAVF</a>) to plunge.
President Donald Trump announced on Saturday a U.S.-<a href="https://www.benzinga.com/markets/equities/25/05/45336288/india-pakistan-ceasefire-teeters-as-blasts-shatter-calm-in-kashmir">brokered ceasefire </a>between India and Pakistan.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45368511/china-to-us-goods-shipment-jump-after-90-day-tariff-postponement-a-big-backlog-is-looming" target="_blank" rel="noreferrer noopener">China To US Goods Shipment Jump After 90-Day Tariff Postponement: &#8216;A Big Backlog Is Looming&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

DUAVF

This Chinese Defense Stock Soared Over 41% In 5 Days: What's Going On?

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) affirms FY2025 sales outlook from $75.00 million-$90.00 million to $75.00 million-$90.00 million vs $82.49 million estimate.

YMAB

Y-mAbs Therapeutics Affirms FY2025 Sales Guidance of $75.00M-$90.00M vs $82.49M Est

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) sees Q2 sales of $17.000 million-$19.000 million vs $19.61 million analyst estimate.

Y-mAbs Therapeutics Sees Q2 Sales $17.000M-$19.000M vs $19.61M Est

Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.64 by 1.56 percent. This is a 1725 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $4.84 billion which missed the analyst consensus estimate of $4.89 billion by 1.03 percent. This is a 29.65 percent increase over sales of $3.73 billion the same period last year.

Sea Q1 EPS $0.65 Beats $0.64 Estimate, Sales $4.84B Miss $4.89B Estimate

Needham analyst Joseph Stringer maintains Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) with a Buy and lowers the price target from $16 to $11.

ANNX

Needham Maintains Buy on Annexon, Lowers Price Target to $11

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) by 40 percent. This is a 20 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $20.90 million which beat the analyst consensus estimate of $19.61 million by 6.62 percent. This is a 4.88 percent increase over sales of $19.93 million the same period last year.

Y-mAbs Therapeutics Q1 EPS $(0.12) Beats $(0.20) Estimate, Sales $20.90M Beat $19.61M Estimate

Teleflex Reports Titan SGS Stapler Associated With Lower Post-Operative GERD Rates In 7-Year Retrospective Study Of Robotic Sleeve Gastrectomy Patients

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) today announced the appointment of Stephen J. Hemsley as its chief executive officer, effective immediately, following Andrew Witty's decision to step down as CEO for personal reasons. Hemsley, who served as company CEO from 2006-2017, will remain chairman of the company's Board of Directors and Witty will serve as a senior adviser to Hemsley.
Additionally, the company suspended its 2025 outlook as care activity continued to accelerate while also broadening to more types of benefit offerings than seen in the first quarter, and the medical costs of many Medicare Advantage beneficiaries new to UnitedHealthcare remained higher than expected.
The company expects to return to growth in 2026.

Comments

Qualigen Therapeutics

Noticias

Últimas noticias sobre Qualigen Therapeutics (NASDAQ:QLGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL